Slide 1: Cliramitug royalty acquisition
Cliramitug royalty acquisition July 2026
Slide 2: Forward Looking Statements
2 Forward Looking Statements This presentation has been prepared by Royalty Pharma plc (the “Company”), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. The information set forth herein does not purport to be complete o
Slide 3: Key messages
3 Key messages 1 2 3 AstraZeneca’s cliramitug in Phase 3 Impressive clinical results with Expanding market drives multi- development for ATTR-CM potential to reverse disease blockbuster sales potential Cliramitug a first-in-class TTR-fibril Cliramitug designed to remove amyloid AstraZeneca guidance
Slide 4: Cliramitug royalty acquisition overview
4 Cliramitug royalty acquisition overview Transaction overview Royalty terms AZN’s cliramitug peak sales potential(3) Transaction terms Royalty rate • Up to $425m, including $125m upfront for a • 3.75% on worldwide sales portion of Neurimmune’s existing royalty(1) Stakeholders Royalty payments • Sel
Slide 5: Cliramitug Phase 1 results support meaningful heart function benefit
5 Cliramitug Phase 1 results support meaningful heart function benefit Unprecedented decline in biomarkers strongly correlated with improved CV outcomes; not seen before in approved TTR therapies ECV: imaging biomarker for amount of amyloid in heart(1,2) NT-proBNP: heart wall stress(1,2) (Cliramitug
Slide 6: Amyloid depleters the next potential wave of innovation in ATTR-CM
6 Amyloid depleters the next potential wave of innovation in ATTR-CM Currently approved TTR therapies TTR therapies in development(2) Therapy Mechanism Marketer Indications Dosing Therapy Mechanism Marketer Phase 3 results(3) Dosing Amvuttra Silencer CM & PN Sub-Q (Q3M) Cliramitug Depleter CM (2028)
Slide 7: ATTR-CM market is large, underserved and growing
7 ATTR-CM market is large, underserved and growing ATTR-CM market sales by product(1) Significant ATTR-CM growth opportunity(2) ~70% CAGR >$7bn >500K ~200K ~80% Global patients U.S. patients Untreated ~$5bn U.S. patients ~$3bn Attractive ~15K new to Diagnosis and opportunity to treatment treatment r